Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry

TY - JOUR

T1 - Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes

T2 - a report from the prospective European LeukaemiaNet MDS (EUMDS) registry

AU - de Swart, Louise

AU - Smith, Alexandra Gwen

AU - Johnston, Thomas W.

AU - Haase, Detlef

AU - Droste, Jackie

AU - Fenaux, Pierre

AU - Symeonidis, Argiris

AU - Sanz, Guillermo

AU - Hellström-Lindberg, Eva

AU - Cermák, Jaroslav

AU - Germing, Ulrich

AU - Stauder, Reinhard

AU - Georgescu, Otilia

AU - MacKenzie, Marius

AU - Malcovati, Luca

AU - Holm, Mette S

AU - Almeida, Antonio M

AU - Mądry, Krzysztof

AU - Slama, Borhane

AU - Guerci-Bresler, Agnes

AU - Sanhes, Laurence

AU - Beyne-Rauzy, Odile

AU - Luño, Elisa

AU - Bowen, David

AU - de Witte, Theo

N1 - © 2015 John Wiley & Sons Ltd.

PY - 2015

Y1 - 2015

N2 - Baseline characteristics, disease-management and outcome of 1000 lower-risk myelodysplastic syndrome (MDS) patients within the European LeukaemiaNet MDS (EUMDS) Registry are described in conjunction with the validation of the revised International Prognostic Scoring System (IPSS-R). The EUMDS registry confirmed established prognostic factors, such as age, gender and World Health Organization 2001 classification. Low quality of life (EQ-5D visual analogue scale score) was significantly associated with reduced survival. A high co-morbidity index predicted poor outcome in univariate analyses. The IPSS-R identified a large group of 247 patients with Low (43%) and Very low (23%) risk score within the IPSS intermediate-1 patients. The IPSS-R also identified 32 High or Very high risk patients within the IPSS intermediate-1 patients. IPSS-R was superior to the IPSS for predicting both disease progression and survival. Seventy percent of patients received MDS-specific treatment or supportive care, including red blood cell transfusions (51%), haematopoietic growth factors (58%) and iron chelation therapy (8%), within 2 years of diagnosis; while 30% of the patients only required active monitoring. The IPSS-R proved its utility as a more refined risk stratification tool for the identification of patients with a very good or poor prognosis and in this lower-risk MDS population.

AB - Baseline characteristics, disease-management and outcome of 1000 lower-risk myelodysplastic syndrome (MDS) patients within the European LeukaemiaNet MDS (EUMDS) Registry are described in conjunction with the validation of the revised International Prognostic Scoring System (IPSS-R). The EUMDS registry confirmed established prognostic factors, such as age, gender and World Health Organization 2001 classification. Low quality of life (EQ-5D visual analogue scale score) was significantly associated with reduced survival. A high co-morbidity index predicted poor outcome in univariate analyses. The IPSS-R identified a large group of 247 patients with Low (43%) and Very low (23%) risk score within the IPSS intermediate-1 patients. The IPSS-R also identified 32 High or Very high risk patients within the IPSS intermediate-1 patients. IPSS-R was superior to the IPSS for predicting both disease progression and survival. Seventy percent of patients received MDS-specific treatment or supportive care, including red blood cell transfusions (51%), haematopoietic growth factors (58%) and iron chelation therapy (8%), within 2 years of diagnosis; while 30% of the patients only required active monitoring. The IPSS-R proved its utility as a more refined risk stratification tool for the identification of patients with a very good or poor prognosis and in this lower-risk MDS population.

U2 - 10.1111/bjh.13450

DO - 10.1111/bjh.13450

M3 - Article

C2 - 25907546

SN - 0007-1048

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -